TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06903611: CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye

Sponsor: Cambium Bio Limited · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 475 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT06903611 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06903611 Rescue Dossier →